Dr. Keating is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
MD Anderson Cancer Ctr, Unit 428
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1974 - 1975
University of Melbourne Faculty of MedicineClass of 1966
Certifications & Licensure
TX State Medical License 1975 - 2025
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach Start of enrollment: 2001 Dec 01
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Publications & Presentations
PubMed
- Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations.Panpan Liu, Kefeng Wang, Jianan Li, Marcia A Ogasawara, Zhongjun Xia, William G Wierda, Michael J Keating, Yiqing Li, Peng Huang> ;Haematologica. 2024 Feb 1
- 5 citationsSustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.Philip A Thompson, Alexandre Bazinet, William G Wierda, Constantine S Tam, Susan M O'Brien, Satabdi Saha, Christine B Peterson, William Plunkett, Michael J Keating> ;Blood. 2023 Nov 23
- 2 citationsVenetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.Philip A Thompson, Michael J Keating, Alessandra Ferrajoli, Nitin Jain, Christine B Peterson, Naveen Garg, Sa A Wang, Jeffrey L Jorgensen, Tapan M Kadia, Prithviraj Bo...> ;Leukemia. 2023 Jul 1
- Join now to see all
Journal Articles
- Trisomy 12 Chronic Lymphocytic Leukemia Expresses a Unique Set of Activated and Targetable PathwaysMichael J Keating, Lynne V Abruzzo, Haematologica
- A Pilot Study of Lower Doses of Ibrutinib in Patients with Chronic Lymphocytic LeukemiaNitin Jain, Michael J Keating, Varsha Gandhi, William G Wierda, Blood
Press Mentions
What Options Are Available for CLL Patients Who Relapse After Ibrutinib?February 21st, 2019
Grant Support
- Clinical Research CoreNational Cancer Institute2006–2010
- Clinical ConsortiumNational Cancer Institute2000–2002
- Clinical ConsosrtiumNational Cancer Institute1999
Professional Memberships
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
